Anzhelika Vorobyeva
Tomsk Polytechnic University
CancerBiophysicsMolecular imagingChemistryConjugateIn vitroIn vivoDARPinBiodistributionPretargetingTrastuzumabDOTAKidneyAffibody moleculeRadionuclide therapyCancer researchScaffold proteinMedicineSelection (genetic algorithm)Pharmacology
56Publications
8H-index
282Citations
Publications 60
Newest
Source
#1O.D. Bragina (RAS: Russian Academy of Sciences)H-Index: 1
#2V. I. Chernov (RAS: Russian Academy of Sciences)H-Index: 1
Last. V.M. Tolmachev (Tomsk Polytechnic University)
view all 7 authors...
Source
#1Olga Bragina (RAS: Russian Academy of Sciences)H-Index: 3
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Vladimir Tolmachev (Uppsala University)H-Index: 51
view all 16 authors...
Radionuclide molecular imaging of human epidermal growth factor (HER2) expression may be helpful to stratify breast and gastroesophageal cancer patients for HER2-targeting therapies. ADAPTs (albumin-binding domain derived affinity proteins) are a new type of small (46-59 amino acids) proteins useful as probes for molecular imaging. The aim of this first-in-human study was to evaluate biodistribution, dosimetry, and safety of the HER2-specific 99mTc-ADAPT6. METHODS: Twenty-nine patients with prim...
7 CitationsSource
#1Haozhong DingH-Index: 3
#2Tianqi XuH-Index: 2
Last. Anzhelika VorobyevaH-Index: 8
view all 8 authors...
Source
#1Maryam Oroujeni (Uppsala University)H-Index: 7
#2Sara S. Rinne (Uppsala University)H-Index: 8
Last. Vladimir TolmachevH-Index: 51
view all 10 authors...
Radionuclide imaging of HER2 expression in tumours may enable stratification of patients with breast, ovarian, and gastroesophageal cancers for HER2-targeting therapies. A first-generation HER2-binding affibody molecule [99mTc]Tc-ZHER2:V2 demonstrated favorable imaging properties in preclinical studies. Thereafter, the affibody scaffold has been extensively modified, which increased its melting point, improved storage stability, and increased hydrophilicity of the surface. In this study, a secon...
Source
#1Hanna TanoH-Index: 1
#2Maryam OroujeniH-Index: 7
Last. Vladimir TolmachevH-Index: 51
view all 10 authors...
Affibody-mediated PNA-based pretargeting is a promising approach to radionuclide therapy of HER2-expressing tumors. In this study, we test the hypothesis that shortening the PNA pretargeting probes would increase the tumor-to-kidney dose ratio. The primary probe ZHER2:342-SR-HP15 and the complementary secondary probes HP16, HP17, and HP18, containing 9, 12, and 15 nucleobases, respectively, and carrying a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) chelator were designed, syn...
Source
#1Javad Garousi (Uppsala University)H-Index: 13
#2Emma von Witting (KTH: Royal Institute of Technology)H-Index: 4
Last. Sophia Hober (KTH: Royal Institute of Technology)H-Index: 38
view all 11 authors...
1 CitationsSource
#1Tianqi XuH-Index: 2
#2Haozhong DingH-Index: 3
Last. Torbjörn GräslundH-Index: 21
view all 7 authors...
The human epidermal growth factor receptor 2 (HER2) is frequently overexpressed in a variety of cancers and therapies targeting HER2 are routinely used in the clinic. Recently, small engineered scaffold proteins, such as affibody molecules, have shown promise as carriers of cytotoxic drugs, and these drug conjugates may become complements or alternatives to the current HER2-targeting therapies. Here, we investigated if a monovalent HER2-binding affibody molecule, ZHER2:2891, fused with a plasma ...
1 CitationsSource
#1Anders Myrhammar (KTH: Royal Institute of Technology)H-Index: 1
#2Anzhelika Vorobyeva (Uppsala University)H-Index: 8
Last. M. Altai (Lund University)H-Index: 2
view all 9 authors...
Source
#1Anzhelika Vorobyeva (Uppsala University)H-Index: 8
#2Ekaterina Bezverkhniaia (Tomsk Polytechnic University)H-Index: 1
Last. Vladimir Tolmachev (Uppsala University)H-Index: 51
view all 10 authors...
Efficient treatment of disseminated triple-negative breast cancer (TNBC) remains an unmet clinical need. The epithelial cell adhesion molecule (EpCAM) is often overexpressed on the surface of TNBC cells, which makes EpCAM a potential therapeutic target. Radionuclide molecular imaging of EpCAM expression might permit selection of patients for EpCAM-targeting therapies. In this study, we evaluated a scaffold protein, designed ankyrin repeat protein (DARPin) Ec1, for imaging of EpCAM in TNBC. DARPi...
1 CitationsSource